drugset / Trial / NCT03928288
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Phase 2
Completed
129 enrolled
Boston Children's Hospital
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabChildren's Hospital Colorado · collabStanford University · collabThomas Jefferson University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial proposes a novel, non-hormonal, non-surgical therapeutic approach aimed at alleviating the pain and suffering associated with this common chronic disease that currently has limited treatment options.
Timeline
- Start
- 2019-12-02
- Primary completion
- 2026-01-14
- Completion
- 2026-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabergoline | Small molecule | 0.5 mg | Oral |